Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Overview
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Companies Involved in Therapeutics Development
ABIONYX Pharma SA
Advent Therapeutics Inc
Avecho Biotechnology Ltd
Bausch Health Companies Inc
Boehringer Ingelheim Intertiol GmbH
Galderma SA
Galephar Pharmaceutical Research Inc
Ipsen SA
Lee’s Pharmaceutical Holdings Ltd
Orphanix GmbH
Ortho Dermatologics Inc
Promius Pharma LLC
Sveikatal Inc
TherapyX Inc
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Drug Profiles
(adapalene + benzoyl peroxide + clindamycin phosphate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(adapalene + clindamycin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(benzoyl peroxide + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(TPX-6001 + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alitretinoin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alitretinoin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bexarotene + CD-1530 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palovarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ROR-Gamma for Autoimmune Disorders, Allergies and Spondylosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules 1 to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize RARG for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tazarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tazarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tretinoin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tretinoin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tretinoin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trifarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Dormant Products
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Discontinued Products
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Product Development Milestones
Featured News & Press Releases
Aug 04, 2021: Health Cada approves ARAZLO (Tazarotene) Lotion, 0.045%, first such lotion treatment for acne vulgaris
May 28, 2021: Ipsen confirms U.S. FDA accepts new drug application for Palovarotene as the first potential treatment worldwide for fibrodysplasia ossificans progressiva (FOP)
Apr 22, 2021: Ortho Dermatologics announces statistically significant topline results from second pivotal phase 3 clinical trial evaluating IDP-126 gel in acne vulgaris
Apr 21, 2021: Ortho Dermatologics to present abstract on ARAZLO (tazarotene) Lotion at 2021 American Academy of Dermatology Annual Meeting
Feb 24, 2021: Galderma and Aklief (trifarotene) cream, 0.005% unveil me being me campaign to inspire young people with acne to live life to the fullest
Feb 09, 2021: Lee’s Pharmaceutical Holdings: Update on an investigatiol dermatology product
Nov 16, 2020: Trifarotene in moderate acne: no study data for the assessment of the added benefit
Sep 10, 2020: Ipsen to present new Insights at ASBMR for potential treatment of ultra-rare disease Fibrodysplasia Ossificans Progressiva (FOP), including global phase III MOVE Trial results
Aug 25, 2020: Ipsen to present results from MOVE, the first global phase III trial in fibrodysplasia ossificans progressiva (FOP), at ASBMR 2020 annual meeting
Jul 23, 2020: Ortho Dermatologics launches ARAZLO (tazarotene) lotion, 0.045%, in the United States
Jun 23, 2020: Ortho Dermatologics launches ARAZLO (tazarotene) lotion, 0.045%, in the United States
Mar 27, 2020: Ipsen to restart dosing of palovarotene in FOP studies
Jan 27, 2020: Ipsen temporarily stops palovarotene dosing in FOP trials
Jan 13, 2020: Ortho Dermatologics announces publication of pivotal phase 3 data on ARAZLO (tazarotene) Lotion, 0.045% in the Jourl of Drugs in Dermatology (JDD)
Jan 08, 2020: Certara partners with Galderma in advancing modeling and simulation technology to attain FDA approval of AKLIEF topical Acne cream
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by ABIONYX Pharma SA, 2021
Pipeline by Advent Therapeutics Inc, 2021
Pipeline by Avecho Biotechnology Ltd, 2021
Pipeline by Bausch Health Companies Inc, 2021
Pipeline by Boehringer Ingelheim International GmbH, 2021
Pipeline by Galderma SA, 2021
Pipeline by Galephar Pharmaceutical Research Inc, 2021
Pipeline by Ipsen SA, 2021
Pipeline by Lee’s Pharmaceutical Holdings Ltd, 2021
Pipeline by Orphanix GmbH, 2021
Pipeline by Ortho Dermatologics Inc, 2021
Pipeline by Promius Pharma LLC, 2021
Pipeline by Sveikatal Inc, 2021
Pipeline by TherapyX Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021